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Abstract: Alzheimer’s disease (AD) is characterised by the apoptosis of cholinergic neurons and the
consequent attenuation of acetylcholine mediated neurotransmission, resulting in neurodegeneration.
Acetyl-cholinesterase (AChE) and butyryl-cholinesterase (BuChE) are attractive therapeutic targets in
the treatment of AD since inhibition of these enzymes can be used to restore synaptic concentrations
of acetylcholine. Whilst inhibitors for these enzymes such as galantamine and rivastigmine
have been approved for use, none are able to halt the progression of AD and are responsible
for the production of troublesome side-effects. Efficacious cholinesterase inhibitors have been
isolated from natural plant-based compounds with many demonstrating additional benefits beyond
cholinesterase inhibition, such as antioxidation and anti-inflammation, which are key parts of AD
pathology. In this study, five natural flavan-3-ol (catechin) compounds: ((-)-epicatechin (EC), catechin,
(-)-epicatechin-3-gallate (ECG),) (-)-epigallocatechin (EGC), (-)-epigallocatechin-3-gallate (EGCG),
isolated from green tea, were screened for their cholinesterase inhibitory activity using the Ellman
assay. The kinetics of inhibition was determined using reciprocal Lineweaver-Burk plots. EGCG
was the only compound found to produce statistically significant, competitive inhibition, of both
AChE (p < 0.01) and BuChE (p < 0.01) with IC50 values of 0.0148 µmol/mL and 0.0251 µmol/mL
respectively. These results, combined with previously identified antioxidative and anti-inflammatory
properties, highlight the potential use of EGCG in the treatment of AD, provided it can be delivered to
cholinergic neurons in therapeutic concentrations. Further testing of EGCG in vivo is recommended
to fully characterise the pharmacokinetic properties, optimal method of administration and efficacy
of this novel plant-based compound.
Keywords: Alzheimer’s; cholinesterase inhibitors; catechins; flavan-3-ols; acetylcholine;
neurodegeneration
1. Introduction
Alzheimer’s disease is the most common form of dementia in the UK accounting for 50–75% of
cases [1]. Indeed, the number of people with AD in the UK is expected to nearly double by 2040 to
1.6 million patients, with the total cost of treating dementia expected to reach £94.1 bn by 2040 [2]. AD is
an irreversible neurodegenerative disorder in which there is a progressive and continual deterioration
in cognitive function [3]. Initial symptoms typically include confusion, repetitive questioning and
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changes in mood [4]. These symptoms progressively worsen with patients beginning to experience
delusion and aphasia until eventually suffering from difficulties with breathing, eating and moving,
especially without significant assistance from carers [4].
The aetiology and pathophysiology of AD is complex and is characterized by the apoptosis of
cholinergic neurons, especially those in the limbic and neocortical regions [5] and the consequent
attenuation of acetylcholine mediated neurotransmission. This cholinergic neuronal apoptosis is
thought to result primarily from the abnormal production and processing of the β-amyloid and tau
proteins [6–10]. In addition to this, there is increasing recognition that the immune system, and
the subsequent inflammatory cascades it stimulates, are also of significant importance [11]. Genetic
susceptibility in the form of polymorphism at the APOE gene locus also appears to modulate risk with
the ε4 variant conferring greater risk of AD development [12].
Consequently, there is considerable interest in the development of effective treatments to alleviate
the symptoms of AD and potentially halt the underlying neurodegeneration the disease causes. Such
treatment should lead to an improved quality of life for patients whilst also reducing the financial
burden that health systems experience as a result of the disease. The loss of cholinergic neurons,
especially those in the limbic and neocortical regions (which are vital for cognitive functions such as
memory, learning and attention [13] leads to diminished acetylcholine (ACh) production [5]. Therefore,
inhibition of Acetylcholinesterase (AChE), the enzyme responsible for ACh metabolism [14], is a key
target in the treatment of AD. Effective inhibition of AChE allows synaptic levels of ACh to be restored,
thus alleviating the symptoms of AD.
In addition, Butyrylcholinesterase (BuChE) has also been identified as another important
cholinesterase relevant to AD [15]. Levels of BuChE expression are increased by up to 120% in
patients with AD, possibly due to compensatory mechanisms which relate to AChE expression which
can be reduced by 55–67% [15]. Consequently, the majority of ACh is metabolised by BuChE in the
later stages of AD.
Therefore, dual inhibition of BuChE, as well as AChE, would be an attractive property for
any potential novel cholinesterase inhibitor. Several AChE inhibitors including galantamine (Gal),
donepezil and rivastigmine have been developed and approved for the treatment of mild AD [16].
Only rivastigmine has been approved for the inhibition of both AChE and BuChE [16], although Gal
has been shown to inhibit BuChE to a certain extent [17]. Gal is currently the treatment of choice for
AD and has a dual mechanism of action, increasing the sensitivity of postsynaptic NMDA receptors as
well as inhibiting AChE [18]. Both of these factors work to enhance cholinergic neurotransmission.
However, despite its efficacy, Gal results in unpleasant side-effects which include cardiac arrhythmias,
GI irritation and tremor [19]. These side-effects combined with the fact that Gal is unable to halt the
underlying progression of AD means that there is significant interest in the identification of superior
alternatives concerning both efficacy and side-effect profile.
Multiple compounds with anti-cholinesterase activity have been derived from natural plant-based
sources [20]. These natural compounds often have multiple, wide-ranging health benefits beyond
cholinesterase inhibition such as antioxidation and anti-inflammation.
Consequently, natural compounds offer an attractive proposition for the identification of effective
AD treatments since they have the potential to improve symptoms by targeting multiple parts of AD
pathology, including inflammation and the generation of reactive oxygen species [11].
Flavan-3-ols are an example of a class of naturally occurring compounds, found mostly in green
tea, which have been shown to possess antioxidant and anti-inflammatory properties [21]. The average
cup of green tea is estimated to contain a total of 67 mg of these flavan-3-ol compounds [22].
In addition, studies in human clinical trials have demonstrated the ability of flavan-3-ol compounds
to slow cognitive decline [23]. Consequently, flavan-3-ols are an attractive source from which to
identify novel cholinesterase inhibitors. Table 1 summarises the five flavan-3-ol compounds which
were investigated in this study along with Gal, the gold standard for AChE inhibition.
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Table 1. Compound summary table: an overview of the chemicals assessed in this study with structures
and notes for each shown. Chemical structures were produced using ChemDrawTM.
Compound Structure Notes
Galantamine
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Based n this information, it was hypothesised that the beneficial effects of these flavan-3-ol
compounds extended to cholinesterase inhibition.
2. Materials and Meth ds
Acetylchol nesterase (AChE) (EC 3.1.1.7) from electric eel, Butyrylcholi esterase (BuChE)
(EC 3.1.18), from equine serum, acetylthiocholine iodide (ATC), butyrylthiocholine iodide (BTC),
5:5-dithiobis-2-nitrobenzoic acid (DTNB), sodium phosphate (mono and dibasic), sodium bicarbonate,
Galanthamine hydrobromide from Lycoris sp, (-)-epicatechin (EC), catechin, (-)-epicatechin-3-gallate
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(ECG), (-)-epigallocatechin (EGC) and (-)-epigallocatechin-3-gallate (EGCG) were purchased from
Sigma-Aldrich (UK).
2.1. Ellman Essay
The Ellman assay was used to quantify inhibition of the cholinesterase enzymes [26] with some
modification [27]. In brief, 5 µL of AChE isolated from the electric eel (0.03 U/mL, pH 8 Na3PO4 buffer)
or 5 µL of BuChE isolated from equine serum (0.03 U/mL, pH 8 Na3PO4 buffer) was added to a generic
96 well plate followed by 200 µL of pH 8 Na3PO4 buffer, 5 µL of DTNB (0.3 mM in pH 7 Na3PO4
buffer) and finally, 5 µL of the inhibitor under investigation (dissolved in de-ionised H2O). Blank (no
inhibitor or enzyme) and control (no inhibitor) samples were also set up with the total volume made
up to 215 µL using pH 8 phosphate buffer prior to incubation. Samples were then mixed for 10 s at
600 rpm and incubated at 30 ◦C for 10 min in the Ascent Multiskan Plate Reader. Following this, 5 µL
of the substrate ATC (0.5 mM in pH 8 Na3PO4 buffer) or BTC was added (0.5 mM in pH 8 Na3PO4
buffer) to each well.
Average absorbance was then measured every 30 s for 6 min at 405 nm. The concentration of each
inhibitor used to initially test for cholinesterase inhibition varied according to solubility (Table 2).
Table 2. Test stock concentrations: inhibitors were first tested at the highest concentration available to
determine if any inhibition was present before further analysis was carried out.
Inhibitor Stock Concentration * (mg/mL) Final Assay Concentration (µmol/mL)
Galantamine 0.125 0.008
Epicatechin Gallate 2.000 0.103
Epicatechin 5.000 0.391
Catechin 5.000 0.391
Epigallocatechin 5.000 0.371
Epigallocatechin Gallate 5.000 0.248
Synergy Mixture 1.250 -
* For Flavan-3-ols: Based on solubility limits.
A test for synergy between four of the flavan-3-ols under investigation was also carried out.
Epicatechin (EC), catechin, epigallocatechin (EGC) and epigallocatechin gallate (EGCG) were mixed in
a 1:1:1:1 ratio resulting in a test concentration for each inhibitor of 1.25 mg/mL in the synergy mixture.
Average absorbance from the blank wells was calculated and subtracted from each control and
inhibitor concentration triplicate absorbance average. Percentage inhibition was then calculated using
the following equation: (mean absorbance with inhibitor/negative control mean absorbance) × 100.
If statistically significant inhibition was observed, a serial dilution was carried out to produce a
range of concentrations from which a concentration-percentage inhibition curve could be constructed
using SigmaPlotTM (Systat Software Inc., San Jose, CA, USA) From these plots, the IC50 value
was calculated.
2.2. Kinetic Analysis: Lineweaver–Burk Plots (L-B)
Kinetics of inhibition was determined using L-B reciprocal plots which were constructed using
SigmaPlotTM. Two concentrations of each inhibitor, as well as a control, were tested for their
anti-cholinesterase activity using four different substrate concentrations (0.5, 0.25, 0.125 and 0.0625 mM).
Results were then plotted on a graph of 1/absorbance against 1/[substrate] and lines were
extrapolated backwards to determine the point at which the three lines intersected. The point of
intersection allows the type of inhibition present to be identified. From these plots, the KM and VMAX
for each inhibitor concentration were calculated by obtaining the gradient and y-intercept for each
trend line from Excel. VMAX was calculated by 1/Y-intercept and KM was calculated by multiplying the
gradient and the VMAX.
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Therefore, for non-competitive inhibitors, the VMAX will be reduced, and the KM will remain the
same—the opposite is true for competitive inhibition [28]. For uncompetitive inhibition, there is a
reduction in both the VMAX and the KM values whilst for mixed inhibition, VMAX decreases and the
KM can either increase or decrease [28].
3. Results
3.1. AChE Inhibition
Percentage inhibition of AChE in the presence of the compounds under investigation is shown in
Table 3.
Table 3. AChE inhibition: shows the results for AChE inhibition activity at the highest concentrations
available for each compound. Only compounds showing statistically significant levels of inhibition
(p < 0.01) were tested further.
Compound Concentration(mg/mL)
Final Assay
Concentration
(µmol/mL)
AChE
Inhibition
(%)
p-Value
Galantamine 0.125 0.008 93.79 p = 0.000
Epicatechin Gallate 2.000 0.103 37.14 p = 0.001
Epicatechin 5.000 0.391 13.48 p = 0.018
Catechin 5.000 0.391 6.45 p = 0.479
Epigallocatechin 5.000 0.371 82.65 p = 0.000
Epigallocatechin Gallate 5.000 0.248 82.35 p = 0.000
Synergy Mixture 1.250 - 99.22 p = 0.000
Of the seven inhibitors tested, five exhibited statistically significant inhibition (p < 0.01), with Gal
showing the most potent AChE inhibitory activity (Table 3). In addition to Gal, ECG, EGC and EGCG
were found to possess significant AChE inhibitory properties and were studied further.
Synergism between four of the flavan-3-ol compounds (EC, catechin, EGC and EGCG) was
observed despite two of the flavan-3-ols, EC and catechin, being identified as inactive when administered
alone. EC and catechin and were found to have no significant inhibition of AChE even at the highest
available concentrations. Therefore, these compounds were not investigated any further.
Serial dilutions for each of the active compounds and the synergistic mixture yielded a range of
concentrations from which IC50 values were calculated (Table 4). Whilst ECG did show statistically
significant inhibition, its potency was too low for an IC50 value to be accurately calculated.
Table 4. Active compound IC50 value comparisons.
Compound AChE IC50 Value (µmol/mL) Fold Difference Relative to Galantamine
Galantamine 0.000466 1.0
Epigallocatechin 0.034100 73.2
Epigallocatechin Gallate 0.014800 31.8
Gal was by far the most potent inhibitor tested with an IC50 value 73.2× and 31.8× more potent
than EGC and EGCG respectively. The IC50 value for the synergistic mixture is expressed in mg/mL
and compared with Gal in Table 5.
Table 5. Synergy mixture IC50 comparisons.
Compound AChE IC50 Value (mg/mL) Fold Difference Relative to Galantamine
Galantamine 0.008 1.0
Synergy Mixture 0.308 40.8
Nutrients 2020, 12, 1090 6 of 14
Again, Gal demonstrates much greater potency with an IC50 value 40.8-fold smaller than that of
the synergy mixture.
A one-way ANOVA with post-hoc Tukey analysis was then used to reveal the minimum inhibitor
concentration required for each compound to achieve statistically significant inhibition of AChE
(Table 6).
Table 6. Threshold concentrations required for AChE inhibition.
Compound Threshold [Inhibitor](µmol/mL)
Galantamine 0.00048
Epigallocatechin 0.02300
Epigallocatechin Gallate 0.03100
The inhibitor concentration threshold required for AChE inhibition varied between compounds
with Gal producing the lowest concentration required for AChE inhibition. Below these concentrations,
no statistically significant inhibition of AChE was detected. The following dose-response curves for
each of the active compounds along with the corresponding IC50 values are shown in Figure 1.
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Figure 1. IC50 plots of AChE inhibition: concentration against percentage inhibition for each of the
active compounds tested. (A) galantamine, (B) epigallocatechin, (C) epigallocatechin-3-gallate and
(D) synergy mixture.
From this data, it was concluded that of the compounds tested, EGCG was the most efficacious
novel cholinesterase inhibitor with the most potent IC50 value.
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Some synergistic effects were observed with similar percentage inhibition obtained for the
synergistic mixture (99.22%) and EGCG (82.35%) despite concentrations of the inhibitors being four
times lower in the synergy mixture than when the compounds were tested individually. Despite these
findings, none of the novel compounds or the synergy mixture was found to inhibit AChE to the same
extent as Gal.
3.2. AChE Inhibition Kinetics
The kinetics of AChE inhibition was then determined for each of the active compounds using the
reciprocal L-B plots shown in Figure 2.
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Figure 2. Lineweaver–Burk plots: (A) Gal, (B) ECG, (C) EGC and (D) EGCG.
From these plots, the VMAX and KM were calculated (Table 7), allowing the type of enzyme
inhibition present to be confirmed.
Gal and EGCG were found to competitively inhibit AChE (Figure 1, Table 7), whereas ECG and
EGC were found to be uncompetitive inhibitors of AChE.
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Table 7. Kinetic coefficients.
Inhibitor [Inhibitor] (mg/mL) [Inhibitor] (µmol/mL) VMAX (mM) KM (mM)
Galantamine
0.000 0.000 0.055 0.083
0.125 0.008 0.026 1.564
0.250 0.015 0.071 6.177
Epicatechin Gallate
0.000 0.000 0.049 0.087
1.000 0.051 0.041 0.075
2.000 0.103 0.030 0.074
Epigallocatechin
0.000 0.000 0.053 0.107
2.500 0.186 0.013 0.025
5.000 0.371 0.009 0.027
Epigallocatechin
Gallate
0.000 0.000 0.032 0.048
2.500 0.124 0.014 0.094
5.000 0.248 0.081 5.305
3.3. BuChE Inhibition
Compounds were then tested for their ability to inhibit BuChE. Percentage inhibition and the
corresponding p-values obtained from two-sample t-tests are shown in Table 8.
Table 8. BuChE inhibition: initial tests for BuChE inhibition at the highest concentrations available for
each compound. Only compounds showing statistically significant levels of inhibition (p < 0.01) were
tested further.
Compound Concentration(mg/mL)
Final Assay
Concentration (µmol/mL)
BuChE
Inhibition (%) p-Value
Galantamine 0.125 0.008 93.79 p = 0.000
Epicatechin Gallate 2.000 0.103 45.65 p = 0.001
Epicatechin 5.000 0.391 11.62 p = 0.272
Catechin 5.000 0.391 18.26 p = 0.097
Epigallocatechin 5.000 0.371 47.72 p = 0.001
Epigallocatechin Gallate 5.000 0.248 89.64 p = 0.000
Synergy Mixture 1.250 - 56.02 p = 0.000
Gal and EGCG were the only compounds that showed extensive inhibition of BuChE, which
was high enough for IC50 values to be calculated. Whilst ECG (45.65%), EGC (47.72%) and the
synergy mixture (56.02%) did show statistically significant inhibition, this extent of inhibition at high
concentrations is unlikely to have any relevance clinically. Consequently, these inhibitors were not
investigated any further concerning BuChE inhibition.
IC50 values were then calculated and again Gal was found to be more potent than EGCG in terms
of BuChE inhibition (Table 9).
Table 9. BuChE inhibition.
Compound BuChE IC50 Value (µmol/mL) Fold Difference Relative to Galantamine
Galantamine 0.01000 1.00
Epigallocatechin Gallate 0.02510 2.51
Gal was 2.51× more potent than EGCG. This is a much smaller difference, suggesting reduced Gal
affinity for the BuChE enzyme.
A one-way ANOVA with post-hoc Tukey analysis revealed the minimum inhibitor concentration
required for statistically significant inhibition BuChE to be achieved (Table 10).
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Table 10. Threshold concentrations required for BuChE inhibition.
Compound Threshold [Inhibitor] (µmol/mL)
Galantamine 0.0313
Epigallocatechin Gallate <0.001
The lowest concentration of EGCG tested was sufficient to produce significant inhibition.
Consequently, a higher minimum concentration of Gal was required to achieve statistically significant
inhibition of BuChE. The IC50 plots for BuChE inhibition with Gal and EGCG are shown in Figure 3.
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Figure 3. IC50 plots for BuChE inhibition: concentration against percentage inhibition for each of the
active compounds tested. (A) Gal and (B) EGCG.
EGCG was identified as the most effective novel inhibitor of BuChE. Although EGCG was less
potent than Gal, the difference in the amount of BuChE inhibition produced is relatively small.
3.4. BuChE Inhibition Kinetics
The kinetics of BuChE inhibition was again determined using L-B plots (Figure 4).
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Gal appears to exhibit mixed inhibition (Figure 4A, Table 11). In contrast, EGCG demonstrates
competitive inhibition (Figure 4B, Table 11).
Table 11. Kinetic coefficients.
[Inhibitor] (mg/mL) [Inhibitor] (mg/mL) [Inhibitor] (µmol/mL) VMAX (mM) KM (mM)
Galantamine
0.000 0.000 0.096 0.175
0.125 0.008 0.072 0.501
0.500 0.031 0.043 0.651
Epigallocatechin
Gallate
0.000 0.000 0.054 0.172
0.125 0.124 0.021 0.293
0.250 0.248 0.030 1.863
3.5. Cholinesterase Affinity Comparison
EGCG was the only novel compound identified as a significant inhibitor of both cholinesterase
enzymes. Varying affinity of EGCG for the AChE and BuChE enzymes was identified (Table 12).
Table 12. IC50 comparison for AChE and BuChE.
Compound AChE IC50 Value(µmol/mL)
BuChE IC50 Value
(µmol/mL)
Selectivity for
AChE
Galantamine 0.000466 0.01000 21.5
Epigallocatechin Gallate 0.014800 0.02510 1.7
Calculated IC50 values demonstrated that Gal was 21.5-fold more selective for AChE than BuChE.
A similar but much smaller difference in selectivity was identified for EGCG which had an AChE IC50
value 1.7-fold smaller than the corresponding BuChE IC50 value.
Finally, synergism was observed between flavan-3-ol compounds, producing statistically
significant inhibition of both AChE and BuChE (Table 13).
Table 13. Synergy mixture cholinesterase inhibition comparison: the synergy mixture was much more
effective at inhibiting AChE although relevant inhibition of BuChE was still detected.
Compound AChE Inhibition (%) BuChE Inhibition (%)
Synergy Mixture 99.22 56.02
Synergism was more pronounced for inhibition of AChE, resulting in 43.20% more inhibition than
for BuChE.
4. Discussion
4.1. Findings
Analysis of six novel plant-based compounds using the Ellman assay allowed for the identification
of significant AChE inhibitory properties in two of the novel compounds studied, EGC and EGCG,
and significant BuChE inhibitory properties in one compound, EGCG.
Of the flavan-3-ols investigated, only EGCG possessed significant inhibition of both cholinesterase
enzymes. Inhibition of AChE and BuChE is likely to be beneficial as both enzymes have been shown to
modulate cholinergic neurotransmission which is key in the pathology of AD [15]. Moreover, in the
later stages of AD, BuChE is responsible for the majority of ACh metabolism [15].
Synergism was also identified between four of the flavan-3-ol compounds for AChE inhibition
and to a lesser extent, BuChE inhibition. This is of importance because these compounds are likely to
be consumed in combination since they are all found in green tea [29]. The varying kinetics of AChE
Nutrients 2020, 12, 1090 11 of 14
inhibition produced by EGC (uncompetitive) and EGCG (competitive) may account for some of this
synergism. Synergy is a known phenomenon in natural product extracts [30].
However, despite some of the novel compounds achieving statistically significant inhibition of
cholinesterase enzymes, Gal (the current gold-standard of treatment) was able to produce IC50 values
much more potent than all of the novel compounds in all experiments conducted.
An IC50 value of 0.466 µM was calculated for Gal inhibition of AChE. This is substantially different
from a previously calculated value in another study of 4 µM [31]. This discrepancy may be accounted
for by differing experimental procedures. Differences in the type of AChE used are likely to change
calculated IC50 values. Moreover, the same protocol was used for each experiment in this investigation,
meaning that the comparisons made between the compounds under investigation are still valid.
Gal was found to competitively inhibit AChE, a finding which is consistent with existing
literature [18]. However, in this experiment, inhibition of BuChE by Gal was found to be mixed. This
finding may again be a result of different experimental procedures.
4.2. Bioavailability and Cellular Accumulation of Flavan-3-Ols
A key aim in the development of new cholinesterase inhibitors is to develop compounds which
have side-effect profiles superior to that of Gal. Therefore, assessment of flavan-3-ol compounds
in vivo is also important for the identification of any potential side-effects. If flavan-3-ol compounds
are shown to have a favourable side-effect profile along with cholinesterase inhibition, they may be an
attractive alternative to Gal, with the reduced potency of flavan-3-ols compared to Gal being offset by
a more desirable side-effect profile.
Studies have shown that concentrations of flavan-3-ols between 1–100 µmol/L in human cells
are sufficient to produce benefits such as antioxidation and anti-inflammation [32]. However, oral
administration, the consequent metabolism and limited passive absorption from the gastrointestinal
tract, results in flavan-3-ol compounds being able to produce only very low plasma concentrations,
typically below the micromolar range [32]. These factors combined with an estimated blood–brain–
barrier (BBB) penetrative ability of only 2.8% for EGCG in mice [25] suggests only very small
concentrations of flavan-3-ols are likely to be able to reach cholinergic neurons in the brain. However,
differences in the BBB permeability to flavan-3-ols may exist between mice and humans and this
highlights the need for in vivo human testing.
Despite the significant anti-cholinesterase properties in vitro of EGCG shown, concentrations
achieved naturally inside human cells are unlikely to be sufficient to replicate this significant
cholinesterase inhibition. Consequently, Gal appears likely to remain the treatment of choice unless
novel methods of drug delivery can be developed. Nano delivery has shown some promise and could
be used to enhance flavan-3-ol bioavailability [33].
Another alternative could be to develop new formulations for flavan-3-ol delivery. It has been
shown that the formulation of flavan-3-ols with ascorbic acid (vitamin C) and sucrose resulted in
enhanced bioavailability [34]. Increasing bioavailability is vital in ensuring therapeutic levels of
flavan-3-ol compounds can reach the cholinergic neurons for effective cholinesterase inhibition to be
achieved. In addition, ascorbic acid has also been shown to counteract the iron depletion and reduced
absorption of nutrients from the gastrointestinal tract that can result from the intake of large quantities
of dietary flavan-3-ols [35].
An understanding of the genetic polymorphisms affecting the expression and function of the
transporters and enzymes which determine the bioavailability of flavan-3-ols is also important.
The DTDST transporter has been identified as a relevant transporter in the uptake of flavan-3-ol
compounds from the intestines in mice [36]. Functionally relevant polymorphisms in the genes
encoding for transporters such as DTDST can lead to altered pharmacokinetic profiles for flavan-3-ol
compounds, which in-turn may limit the efficacy of these compounds to specific groups of patients.
One of the limitations of this study was the use of L-B plots as these can skew the results from
experiments. This is because taking the reciprocal of results causes the magnification of errors for
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smaller values whilst larger values are not affected to the same extent [28]. Despite using electric eel
AChE, human CNS AChE shares a large amount of homology with electric eel AChE [37]. Therefore,
electric eel AChE can be considered a suitable, more cost-effective alternative for use in the Ellman
assay. Equine BuChE shares up to 93.4% sequence homology with human BuChE [38] and this makes
equine serum BuChE a suitable model for this experiment.
4.3. Alternative Approaches
Recently, greater emphasis has been placed on prevention of AD in the first place, especially
since the onset of the disease is currently thought to start many years before patients present with
symptoms [39]. Reductions in AD incidence have been recorded in the UK over recent years and it is
hypothesised that these reductions are attributable to decreased exposure to well-established AD risk
factors [40]. Therefore, despite the promise that flavan-3-ols show as novel cholinesterase inhibitors for
the treatment of AD, they could be evaluated in the context of preventative medication, possibly being
used to mitigate the negative effects of exposure to AD risk factors.
Finally, the combination of this preventative treatment with the use of models which can assign
individuals a hazard score according to their genetic profile [41], predicting the likelihood of them
developing AD, should allow further reductions in the incidence of AD to be achieved.
5. Conclusions
Treatment with natural plant-based compounds such as flavan-3-ols could be used to provide more
holistic benefits, targeting age-associated memory impairment or multiple areas of AD pathology. This
is in contrast to Gal which produces mainly cholinesterase inhibition with troublesome side-effects [19].
The anti-inflammatory and antioxidative properties of flavan-3-ol compounds [32], combined
with significant cholinesterase inhibitory activity demonstrated by EGCG in this study, results in an
attractive group of compounds which could be recommended for the treatment of AD symptoms.
Further investigation of EGCG and other related flavan-3-ols in vivo is suggested to gain a fuller
understanding of the properties of these compounds.
Author Contributions: Conceptualization, E.J.O. Methodology, E.J.O.; validation, E.J.O. and J.M.; formal analysis,
E.J.O. and J.M.; investigation, E.J.O. and J.M.; data curation, E.J.O. and J.M.; writing—original draft preparation,
J.M.; writing—review and editing, E.J.O. and J.M.; supervision, E.J.O. All authors have read and agreed to the
published version of the manuscript.
Funding: This study was supported by the Faculty of Medical Sciences, Newcastle University, (UK).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. NICE. Dementia. 2019. Available online: https://cks.nice.org.uk/dementia (accessed on 20 January 2020).
2. Alzheimer’s Society. Facts for the Media. 2020. Available online: https://www.alzheimers.org.uk/about-us/
news-and-media/facts-media (accessed on 15 March 2020).
3. Gale, S.A.; Acar, D.; Daffner, K.R. Dementia. Am. J. Med. 2018, 131, 1161–1169. [CrossRef]
4. NHS. Alzheimer’s Disease Symptoms. 2018. Available online: https://www.nhs.uk/conditions/alzheimers-
disease/symptoms/ (accessed on 20 January 2020).
5. Hampel, H.; Mesulam, M.M.; Cuello, A.C.; Farlow, M.R.; Giacobini, E.; Grossberg, G.T.; Khachaturian, A.S.;
Vergallo, A.; Cavedo, E.; Snyder, P.J.; et al. The Cholinergic System in the Pathophysiology and Treatment of
Alzheimer’s Disease. Brain 2018, 141, 1917–1933. [CrossRef]
6. Karran, E.; Mercken, M.; Strooper, B.D. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal
for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10, 698–712. [CrossRef]
7. Jarrett, J.T.; Berger, E.P.; Lansbury, P.T., Jr. The carboxy terminus of the beta-amyloid protein is critical for the
seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease. Biochemistry 1993,
32, 4693–4697. [CrossRef]
8. Querfurth, H.W.; LaFerla, F.M. Alzheimer’s disease. N. Engl. J. Med. 2010, 362, 329–344. [CrossRef] [PubMed]
Nutrients 2020, 12, 1090 13 of 14
9. Barbier, P.; Zejneli, O.; Martinho, M.; Lasorsa, A.; Belle, V.; Smet-Nocca, C.; Tsvetkov, P.O.; Devred, F.;
Landrieu, I. Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects. Front.
Aging Neurosci. 2019, 11, 204. [CrossRef] [PubMed]
10. Chintamaneni, M.; Bhaskar, M. Biomarkers in Alzheimer’s disease: A review. ISRN Pharmacol. 2012, 2012,
984786. [CrossRef] [PubMed]
11. Heneka, M.T.; Carson, M.J.; El Khoury, J.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.;
Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol.
2015, 14, 388–405. [CrossRef]
12. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.;
Haines, J.L.; Pericak-Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s
disease in late onset families. Science 1993, 261, 921–923. [CrossRef]
13. Ferreira-Vieira, T.H.; Guimaraes, I.M.; Silva, F.R.; Ribeiro, F.M. Alzheimer’s disease: Targeting the Cholinergic
System. Curr. Neuropharmacol. 2016, 14, 101–115. [CrossRef]
14. McMahan, U.J.; Sanes, J.R.; Marshall, L.M. Cholinesterase is associated with the basal lamina at the
neuromuscular junction. Nature 1978, 271, 172–174. [CrossRef] [PubMed]
15. Li, Q.; Yang, H.; Chen, Y.; Sun, H. Recent progress in the identification of selective butyrylcholinesterase
inhibitors for Alzheimer’s disease. Eur. J. Med. Chem. 2017, 132, 294–309. [CrossRef] [PubMed]
16. Colovic´, M.B.; Krstic´, D.Z.; Lazarevic´-Pašti, T.D.; Bondžic´, A.M.; Vasic´, V.M. Acetylcholinesterase inhibitors:
Pharmacology and toxicology. Curr. Neuropharmacol. 2013, 11, 315–335. [CrossRef] [PubMed]
17. Walsh, R.; Rockwood, K.; Martin, E.; Darvesh, S. Synergistic inhibition of butyrylcholinesterase by galantamine
and citalopram. Biochim. Biophys. Acta 2011, 1810, 1230–1235. [CrossRef] [PubMed]
18. Lilienfeld, S. Galantamine: A novel cholinergic drug with a unique dual mode of action for the treatment of
patients with Alzheimer’s disease. CNS Drug Rev. 2002, 8, 159–176. [CrossRef] [PubMed]
19. NICE. Galantamine. 2018. Available online: https://bnf.nice.org.uk/drug/galantamine.html (accessed on
20 January 2020).
20. Murray, A.P.; Faraoni, M.B.; Castro, M.J.; Alza, N.P.; Cavallaro, V. Natural AChE Inhibitors from Plants and
their Contribution to Alzheimer’s Disease Therapy. Curr. Neuropharmacol. 2013, 11, 388–413. [CrossRef]
21. Grzesik, M.; Naparło, K.; Bartosz, G.; Sadowska-Bartosz, I. Antioxidant properties of catechins: Comparison
with other antioxidants. Food Chem. 2018, 241, 480–492. [CrossRef]
22. Khokhar, S.; Magnusdottir, S.G.M. Total Phenol, Catechin, and Caffeine Contents of Teas Commonly
Consumed in the United Kingdom. J. Agric. Food Chem. 2002, 50, 565–570. [CrossRef]
23. Kuriyama, S.; Hozawa, A.; Ohmori, K.; Shimazu, T.; Matsui, T.; Ebihara, S.; Awata, S.; Nagatomi, R.; Arai, H.;
Tsuji, I. Green tea consumption and cognitive function: A cross-sectional study from the Tsurugaya Project 1.
Am. J. Clin. Nutr. 2006, 83, 355–361. [CrossRef]
24. Grosso, G.; Stepaniak, U.; Topor-Ma˛dry, R.; Szafraniec, K.; Paja˛k, A. Estimated dietary intake and major food
sources of polyphenols in the Polish arm of the HAPIEE study. Nutrition 2014, 30, 1398–1403. [CrossRef]
25. Pervin, M.; Unno, K.; Nakagawa, A.; Takahashi, Y.; Iguchi, K.; Yamamoto, H.; Hoshino, M.; Hara, A.;
Takagaki, A.; Nanjo, F.; et al. Blood-Brain Barrier Permeability of (−)-Epigallocatechin Gallate, its
Proliferation-Enhancing Activity of Human Neuroblastoma SH-SY5Y Cells and its Preventive Effect on
Age-Related Cognitive Dysfunction in Mice. Biochem. Biophys. Rep. 2017, 9, 180–186. [CrossRef]
26. Ellman, G.L.; Courtney, K.D.; Andres, V.; Feather-Stone, R.M. A new and rapid colorimetric determination of
acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–95. [CrossRef]
27. Okello, E.J.; Savelev, S.U.; Perry, E.K. In Vitro anti-beta-secretase and dual anti-cholinesterase activities of
Camellia sinensis L. (tea) relevant to treatment of dementia. Phytother. Res. 2004, 18, 624–627. [CrossRef]
[PubMed]
28. Punekar, N.S. Reversible Inhibitions. In Enzymes: Catalysis, Kinetics and Mechanisms; Punekar, N.S., Ed.;
Springer: Singapore, 2018; pp. 245–257.
29. Tian, M.; Zhang, H.; Row, K.H. Solid-phase extraction of catechin compounds from green tea by catechin
molecular imprinted polymers. Asian J. Chem. 2012, 24, 4606–4610.
30. Savelev, S.; Okello, E.; Perry, N.S.; Wilkins, R.M.; Perry, E.K. Synergistic and antagonistic interactions of
anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol. Biochem. Behav. 2003, 75,
661–668. [CrossRef]
Nutrients 2020, 12, 1090 14 of 14
31. Krátký, M.; Šteˇpánková, Š.; Vorcˇáková, K.; Švarcová, M.; Vinšová, J. Novel Cholinesterase Inhibitors Based
on O-Aromatic N,N-Disubstituted Carbamates and Thiocarbamates. Molecules 2016, 21, 191. [CrossRef]
[PubMed]
32. Cai, Z.-Y.; Li, X.-M.; Liang, J.-P.; Xiang, L.-P.; Wang, K.-R.; Shi, Y.-L.; Yang, R.; Shi, M.; Ye, J.-H.; Lu, J.-L.; et al.
Bioavailability of Tea Catechins and Its Improvement. Molecules 2018, 23, 2346. [CrossRef] [PubMed]
33. Hu, B.; Liu, X.; Zhang, C.; Zeng, X. Food macromolecule based nano delivery systems for enhancing the
bioavailability of polyphenols. J. Food Drug Anal. 2017, 25, 3–15. [CrossRef]
34. Peters, C.M.; Green, R.J.; Janle, E.M.; Ferruzzi, M.G. Formulation with ascorbic acid and sucrose modulates
catechin bioavailability from green tea. Food Res. Int. 2010, 43, 95–102. [CrossRef]
35. Tamilmani, P.; Pandey, M.C. Iron binding efficiency of polyphenols: Comparison of effect of ascorbic acid and
ethylenediaminetetraacetic acid on catechol and galloyl groups. Food Chem. 2016, 197, 1275–1279. [CrossRef]
36. Ishii, S.; Kitazawa, H.; Mori, T.; Kirino, A.; Nakamura, S.; Osaki, N.; Shimotoyodome, A.; Tamai, I.
Identification of the Catechin Uptake Transporter Responsible for Intestinal Absorption of Epigallocatechin
Gallate in Mice. Sci. Rep. 2019, 9, 11014. [CrossRef]
37. Orhan, I.E. Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory
Action. Curr. Neuropharmacol. 2013, 11, 379–387. [CrossRef] [PubMed]
38. Moorad, D.; Chunyuan, L.; Ashima, S.; Bhupendra, D.; Gregory, G. Purification and Determination of the
Amino Acid Sequence of Equine Serum Butyrylcholinesterase. Toxicol. Methods 1999, 9, 219–227. [CrossRef]
39. Crous-Bou, M.; Minguillón, C.; Gramunt, N.; Molinuevo, J.L. Alzheimer’s disease prevention: From risk
factors to early intervention. Alzheimers Res. Ther. 2017, 9, 71. [CrossRef] [PubMed]
40. Matthews, F.E.; Arthur, A.; Barnes, L.E.; Bond, J.; Jagger, C.; Robinson, L.; Brayne, C. Medical Research
Council Cognitive Function and Ageing Collaboration. A two-decade comparison of prevalence of dementia
in individuals aged 65 years and older from three geographical areas of England: Results of the Cognitive
Function and Ageing Study I and II. Lancet 2013, 382, 1405–1412.
41. Desikan, R.S.; Fan, C.C.; Wang, Y.; Schork, A.J.; Cabral, H.J.; Cupples, L.A.; Thompson, W.K.; Besser, L.;
Kukull, W.A.; Holland, D.; et al. Genetic assessment of age-associated Alzheimer disease risk: Development
and validation of a polygenic hazard score. PLoS Med. 2017, 14, e1002258. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
